This segment focuses on the development and commercialization of therapies for Geographic Atrophy (GA), a late-stage form of age-related macular degeneration (AMD) that leads to irreversible vision loss. IVERIC bio's lead product candidate, Zimura (avacincaptad pegol), is a complement C5 inhibitor currently under development. Research and development activities include Phase 3 clinical trials (GATHER2) to evaluate the efficacy and safety of Zimura. The company utilizes advanced technologies and methodologies in drug development, including intravitreal injections and complement pathway modulation. The patient impact is significant, as effective GA treatments can slow disease progression and preserve vision. Market positioning is competitive, with other companies also developing GA treatments. Future opportunities include expanding Zimura's indications and exploring combination therapies. Regulatory and clinical aspects involve FDA approval processes and post-market surveillance. Partnerships and collaborations are crucial for manufacturing and commercialization, as seen with the strategic manufacturing relationship with Catalent Biologics.

This segment concentrates on discovering and developing treatments for various Inherited Retinal Diseases (IRDs), a group of rare genetic disorders that cause progressive vision loss. IVERIC bio is developing therapies for conditions like Leber Congenital Amaurosis type 10 (LCA10) and Stargardt disease (STGD1). Research and development activities include Phase 2b clinical trials for STAR (OPH2005) and preclinical programs for miniCEP290 and miniABCA4. The company employs advanced gene therapy and gene editing technologies to target the underlying genetic mutations causing these diseases. The therapeutic focus is on restoring or preserving vision in patients with IRDs, offering a significant improvement in their quality of life. Market positioning is in the rare disease space, with a focus on unmet medical needs. Future opportunities include expanding the IRD pipeline and exploring novel therapeutic approaches. Regulatory and clinical aspects involve navigating the complexities of orphan drug designation and clinical trial design for rare diseases. Partnerships and collaborations are essential for accessing specialized expertise and resources in the IRD field.